<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746185</url>
  </required_header>
  <id_info>
    <org_study_id>P141204</org_study_id>
    <nct_id>NCT02746185</nct_id>
  </id_info>
  <brief_title>Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban</brief_title>
  <acronym>CASTA-DIVA</acronym>
  <official_title>Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the efficacy and safety of oral rivaroxaban and subcutaneous
      dalteparin in patients with cancer associated thrombosis. It is designed as a non-inferiority
      open label randomized multicenter trial with blinded adjudication of outcome events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with active cancer and symptomatic pulmonary embolism, proximal deep vein
      thrombosis, iliac or caval thrombosis will be randomly assigned to receive either dalteparin
      using the CLOT regimen or to oral rivaroxaban using the conventional dosage given in the
      Einstein studies. Experimental and control treatments will be given for three months. The
      main outcome at three month will include all symptomatic and incidentally discovered venous
      thromboembolic events including pulmonary embolism (either objectively confirmed and death
      due to pulmonary embolism), lower limb and upper limb deep vein thrombosis, iliac, caval and
      visceral thrombosis and any worsening of vascular obstruction which will be collected
      systematically at inclusion and at day 90. The safety end-points will consist of the rate of
      major bleedings and the composite of major and non-major but clinically significant bleedings
      at day 90. All outcome events will be blindly adjudicated by a central independent
      adjudication committee.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic DVT</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including all symptomatic DVT (lower limbs distal and proximal DVTs, iliac and caval thrombosis, visceral thrombosis and deep vein thrombosis of the arm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic PE</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including symptomatic PE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsuspected PE and DVT</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including clinically unsuspected PE and DVT discovered incidentally</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Worsening of pulmonary vascular or venous obstruction</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrent VTE during the 3-month treatment period including worsening of pulmonary vascular obstruction or venous obstruction on the systematic examinations performed at the end of the 3-month treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major and clinically significant bleedings during the 3-month treatment period</measure>
    <time_frame>3 months</time_frame>
    <description>Major bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and includes any bleeding resulting in death; symptomatic bleeding in a critical organ including intracranial, intra spinal, intraocular, retroperitoneal, intra articular and pericardial bleeding and muscle bleeding resulting in compartment syndrome; symptomatic bleeding resulting in a decrease in the hemoglobin concentration of at least 2g/dL or resulting in the transfusion of at least two packs of blood red cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic recurrences of PE or DVT of the legs</measure>
    <time_frame>3 months</time_frame>
    <description>excluding visceral thrombosis, upper extremity deep vein thrombosis and clinically unsuspected PE and DVT diagnosed incidentally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and non-major clinically significant bleedings at day 90</measure>
    <time_frame>3 months</time_frame>
    <description>Clinically significant non-major bleedings are defined as any bleeding requiring hospitalization or a medical intervention including temporary withholding of anticoagulant treatment to stop bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rivaroxaban plasma concentrations</measure>
    <time_frame>3 months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) determined using a liquid chromatography-tandem mass spectrometry method</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Neoplasm</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Low-molecular-weight heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-molecular-weight heparin</intervention_name>
    <description>dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks</description>
    <arm_group_label>Low-molecular-weight heparin</arm_group_label>
    <other_name>dalteparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Social security affiliation

          -  Written informed consent

          -  Solid active cancer, high grade lymphoma or myeloma treated with Immunomodulatory
             drugs (IMiDs) (thalidomide or lenalidomide). Active cancer is defined as the presence
             of measurable disease or ongoing (or planned) chemotherapy, radiotherapy or targeted
             therapy at inclusion.

          -  Histologically or cytologically proven cancer.

          -  Symptomatic venous thromboembolism objectively confirmed diagnosed because of symptoms
             or discovered incidentally

          -  High-risk of recurrent Venous thromboembolism (VTE) defined by a score of 0 or ≥ 1,
             using the following criteria: female sex (+1), lung cancer (+1), breast cancer (-1)
             non metastatic tumor (-2), previous VTE (+1).

        Exclusion Criteria:

          -  Exclusive adjuvant hormonal treatment with no measurable residual disease

          -  Sub-segmental isolated pulmonary embolism (PE) without associated proximal DVT

          -  Isolated distal deep vein thrombosis (DVT) of the legs

          -  Isolated upper-extremity DVT or superior vena cava thrombosis

          -  Isolated visceral thrombosis

          -  Platelet count &lt; 50 000 G/L

          -  Active bleeding

          -  Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
             including cirrhotic patients with Child Pugh B and C

          -  Hemostatic defect with contraindication to anticoagulant treatment at therapeutic
             dosage

          -  Vena cava filter at inclusion

          -  Fibrinolytic therapy within 3 days preceding inclusion

          -  Creatinine clearance &lt; 30 ml/min according to Cockcroft-Gault formula

          -  Previous heparin-induced thrombocytopenia

          -  Anticoagulant treatment at curative dosage for more than 3 days before inclusion

          -  Pregnancy or lack of effective contraceptive treatment for women of childbearing age

          -  Treatment with both strong CYP3A4 and P-glycoprotein (PgP) inhibitors: protease
             inhibitors for HIV disease, systemic ketoconazole

          -  Treatment with a strong CYP3A4 inducer: rifampicin, carbamazepine, phenytoin.

          -  Life expectancy &lt; 3 months

          -  Eastern Cooperative Oncology Group (ECOG) level 3 or 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP - HEGP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens - Medecine vasculaire (003)</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers - Medecin Interne (002)</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espace Artois Santé</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre - Medecine vasculaire (015)</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest - Departement de medecin interne et pneumologie (008)</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage - Medecine interne 1 (014)</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - Medecine vasculaire (007)</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Départemental La Roche sur Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud - Medecine interne (011)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes - Pneumologie (012)</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEGP - Pneumologie et soins intensifs (001)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Soins de support en Cancerologie (020)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Medecin vasculaire et therapeutique (006)</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saine Musse - Service de Medecine Vasculaire (010)</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil - Medecin Vasculaire (019)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>low-molecular weight heparin</keyword>
  <keyword>rivaroxaban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

